Sunday, March 29, 2015

Tuesday Features

Actinium gearing up for pivotal trial in second half

Actinium gearing up for pivotal trial in second half

Actinium Pharmaceuticals (NYSE MKT:ATNM) expects to begin a Phase 3 trial in the second half this year of its Iomab-B drug candidate as a conditioning agent in elderly patients with relapsed/refractory acute myeloid leukemia (AML) prior to a bone marrow transplant (BMT). Kaushik Dave The company also has a second drug candidate, Actimab-A, now in a... [Read more of this feature]


Ocular Therapeutix eyeing sustained drug delivery

Ocular Therapeutix eyeing sustained drug delivery

Ocular Therapeutix (NASDAQ:OCUL) is aiming to transform the treatment of eye diseases with sustained-release therapeutics, creating a paradigm shift from frequently administered topical ophthalmic drugs to an entire course of therapy in as little as a single dose. Amar Sawhney, Ph.D. “We have multiple late-stage product candidates based on our proven... [Read more of this feature]


CombiMatrix sets bold three-year vision

CombiMatrix sets bold three-year vision

Mark McDonough, president and CEO of CombiMatrix (NASDAQ:CBMX), has set a bold three-year vision for the clinical diagnostic lab company, which specializes in cytogenomic testing for prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. Mark McDonough “We’d like to grow the company to a market cap of at least $125-million,... [Read more of this feature]


More Posts From Tuesday Features

Briefs

Ohr Pharma stock tumbles on Phase 2 trial results

Ohr Pharma stock tumbles on Phase 2 trial results

Ohr Pharmaceutical’s (NASDAQ:OHRP) experimental eye drug failed the main goal as a combination therapy in a mid-stage study, sending the company’s shares plunging 67% in the afternoon session on Friday. The study tested the eye-drop solution, OHR-102, in combination with Roche’s injectable eye drug, Lucentis, in patients with the wet age-related... [Read more of this brief]


Atara appoints Eric Dobmeier to board

Atara appoints Eric Dobmeier to board

Atara Biotherapeutics (NASDAQ:ATRA) has appointed Eric Dobmeier, COO of Seattle Genetics, to the board. Mr. Dobmeier joined Seattle Genetics in March 2002 and has served in positions of increasing responsibility since then, most recently as chief business officer from May 2007 to June 2011. Isaac Ciechanover, CEO of Atara, said Mr. Dobmeier’s vast... [Read more of this brief]


Amarantus to start Phase 2b with eltoprazine in PD

Amarantus to start Phase 2b with eltoprazine in PD

Amarantus BioScience Holdings (OTCQB:AMBS) has an active IND application with the neurology division of the FDA to start a Phase 2b program of eltoprazine for the treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID). The company expects to initiate patient enrollment and dosing in a 60-subject clinical study in individuals with... [Read more of this brief]


Transition posts positive AME, renal clearance studies with ELND005

Transition posts positive AME, renal clearance studies with ELND005

Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has reported positive results from two Phase 1 clinical studies of its neuropsychiatric drug candidate ELND005. The studies were an absorption metabolism excretion (AME) study and a renal clearance study. They are specialized clinical pharmacology trials that are required by the FDA for the approval of... [Read more of this brief]


Roth starts Argos Therapeutics at buy

Roth starts Argos Therapeutics at buy

Roth Capital Partners has initiated coverage of Argos Therapeutics (NASDAQ:ARGS) with a “buy” rating and $21 price target, saying the company has the potential to be one of the leaders in cancer immunotherapy. The stock closed at $8.92 on Wednesday. Argos’ proprietary technology platform, Arcelis, is based on the work of Nobel Prize-winning co-founder,... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+